Incidence of Neural Tube Defects in Ontario, 1986-1999

Overview

Journal CMAJ

Date 2002 Aug 21

PMID 12186167

Citations 24

Authors

Enza Gucciardi

Mary-Anne Pietrusiak

Donna L Reynolds

Jocelyn Rouleau

Affiliations

Soon will be listed here.

Abstract

Background: Prenatal screening and the promotion of folic acid intake could affect the incidence of neural tube defects (NTDs). We examined trends in the total NTD incidence, as detected in live births, stillbirths and therapeutic abortions, from 1986 to 1999 in Ontario.

Methods: To capture cases of NTDs we used data from the Canadian Congenital Anomalies Surveillance System and hospital data on therapeutic abortions. We calculated the total incidence of NTDs by combining the numbers of NTDs occurring in live births, stillbirths and therapeutic abortions.

Results: The total NTD incidence rate increased from 11.7 per 10,000 pregnancies in 1986 to 16.2 per 10,000 in 1995, and it subsequently decreased to 8.6 per 10,000 by 1999. The NTD birth rate (live births and stillbirths) decreased from 10.6 per 10,000 births in 1986 to 5.3 per 10,000 in 1999. The rate of therapeutic abortions with an NTD or hydrocephalus rose from 17.5 per 10,000 abortions in 1986 to 50.7 per 10,000 in 1995 and fell to 28.7 per 10,000 abortions in 1999.

Interpretation: The total NTD incidence rate increased from 1986 to 1995, probably because of increased prenatal screening and better detection of NTDs. The decline from 1995 to 1999 may have been due to increased folic acid intake among women at the time of conception.

Citing Articles

Global prevalence of congenital anencephaly: a comprehensive systematic review and meta-analysis.

Salari N, Fatahi B, Fatahian R, Mohammadi P, Rahmani A, Darvishi N Reprod Health. 2022; 19(1):201.

PMID: 36253858 PMC: 9575217. DOI: 10.1186/s12978-022-01509-4.

Parity and the use of folic acid supplementation during pregnancy.

Sharman Moser S, Rabinovitch M, Rotem R, Koren G, Shalev V, Chodick G BMJ Nutr Prev Health. 2020; 2(1):30-34.

PMID: 33235954 PMC: 7664500. DOI: 10.1136/bmjnph-2019-000024.

Folate status of women in Toronto: Implications of folate fortification and supplementation.

Shere M, Kapur B, Koren G Can J Public Health. 2016; 106(8):e509-13.

PMID: 26986912 PMC: 6972110. DOI: 10.17269/cjph.106.5109.

Incidence and Risk Factors of Neural Tube Defects in Kashan, Central Iran.

Talebian A, Soltani B, Sehat M, Zahedi A, Noorian A, Talebian M Iran J Child Neurol. 2015; 9(3):50-6.

PMID: 26401153 PMC: 4577698.

Fortification and health: challenges and opportunities.

Dwyer J, Wiemer K, Dary O, Keen C, King J, Miller K Adv Nutr. 2015; 6(1):124-31.

PMID: 25593151 PMC: 4288271. DOI: 10.3945/an.114.007443.

References

Alembik Y, Dott B, Roth M, Stoll C . Prevalence of neural tube defects in northeastern France, 1979-1992 impact of prenatal diagnosis. Ann Genet. 1995; 38(1):49-53. View

Van Allen M, Fraser F, DALLAIRE L, Allanson J, McLeod D, Andermann E . Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Clinical Teratology Committee, Canadian College of Medical Geneticists. CMAJ. 1993; 149(9):1239-43. PMC: 1485706. View

Roberts H, Moore C, Cragan J, Fernhoff P, Khoury M . Impact of prenatal diagnosis on the birth prevalence of neural tube defects, Atlanta, 1990-1991. Pediatrics. 1995; 96(5 Pt 1):880-3. View

Morris J, Wald N . Quantifying the decline in the birth prevalence of neural tube defects in England and Wales. J Med Screen. 2000; 6(4):182-5. DOI: 10.1136/jms.6.4.182. View

Hendricks K, Simpson J, Larsen R . Neural tube defects along the Texas-Mexico border, 1993-1995. Am J Epidemiol. 1999; 149(12):1119-27. DOI: 10.1093/oxfordjournals.aje.a009766. View

Allen W, Stevenson R, Thompson S, Dean J . The impact of prenatal diagnosis on NTD surveillance. Prenat Diagn. 1996; 16(6):531-5. DOI: 10.1002/(SICI)1097-0223(199606)16:6<531::AID-PD914>3.0.CO;2-1. View

Koren G . Folic acid and neural tube defects. Good news at last!. Can Fam Physician. 1999; 45:2605-6. PMC: 2328671. View

Czeizel A, Dudas I . Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992; 327(26):1832-5. DOI: 10.1056/NEJM199212243272602. View

Smith D . Measuring up: a health surveillance update on canadian children and youth. Paediatr Child Health. 2010; 4(8):551-2. PMC: 2830776. DOI: 10.1093/pch/4.8.551. View

10.

Johnson K, Rouleau J . Temporal trends in Canadian birth defects birth prevalences, 1979-1993. Can J Public Health. 1997; 88(3):169-76. PMC: 6990195. View

11.

Rankin J, Glinianaia S, Brown R, Renwick M . The changing prevalence of neural tube defects: a population-based study in the north of England, 1984-96. Northern Congenital Abnormality Survey Steering Group. Paediatr Perinat Epidemiol. 2000; 14(2):104-10. DOI: 10.1046/j.1365-3016.2000.00246.x. View

12.

. Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986. EUROCAT Working Group. J Epidemiol Community Health. 1991; 45(1):52-8. PMC: 1060702. DOI: 10.1136/jech.45.1.52. View

13.

De Wals P, Trochet C, Pinsonneault L . Prevalence of neural tube defects in the province of Quebec, 1992. Can J Public Health. 1999; 90(4):237-9. PMC: 6979728. View

14.

Velie E, Shaw G . Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989-1991. Am J Epidemiol. 1996; 144(5):473-9. DOI: 10.1093/oxfordjournals.aje.a008953. View

15.

Chan A, Robertson E, Haan E, Keane R, Ranieri E, CARNEY A . Prevalence of neural tube defects in South Australia, 1966-91: effectiveness and impact of prenatal diagnosis. BMJ. 1993; 307(6906):703-6. PMC: 1678685. DOI: 10.1136/bmj.307.6906.703. View

16.

. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet. 1991; 338(8760):131-7. View